España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - sitagliptina malato - excipientes: croscarmelosa sodica - fÁrmacos hipoglucemiantes excluyendo insulinas - inhibidores de la 4 peptidasa (dpp- 4 peptidasa) - sitagliptina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - sitagliptina malato - excipientes: croscarmelosa sodica - fÁrmacos hipoglucemiantes excluyendo insulinas - inhibidores de la 4 peptidasa (dpp- 4 peptidasa) - sitagliptina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zentiva k.s. - sitagliptina hidrocloruro; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

Unión Europea - español - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Venezuela - español - Instituto Nacional de Higiene

genven genericos venezolanos, s.a. - sitagliptina-metformina - comprimidos recubiertos - 50 mg-500 mg

Venezuela - español - Instituto Nacional de Higiene

genven genericos venezolanos s.a./venezuela - sitagliptina-metformina - comprimido - 50 mg - 850 mg

Venezuela - español - Instituto Nacional de Higiene

genven genericos venezolanos, s.a. - sitagliptina-metformina - comprimidos recubiertos - 50 mg-1000 mg

Venezuela - español - Instituto Nacional de Higiene

laboratorios spefar venezolanos, s.a. - sitagliptina - metformina - comprimidos recubiertos - 50 mg - 1000 mg